Loading stock data…
BDSX
$14.94+3.67 (+32.56%)
Pre-Market$14.98+0.04 (+0.27%)· Last close May 5
Biodesix, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Biodesix, Inc. in the Healthcare sector is trading at $14.94. The stock is currently 26% below its 52-week high of $20.21, remaining 53.7% above its 200-day moving average. Technical signals show neutral RSI of 61 and bullish MACD crossover, explaining why BDSX maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 61) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$14.94
Potential Upside
5%
Whystock Fair Value$15.69
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Mean target$30.50+104.1%
Range$22.00 – $40.00
Fundamentals
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$117.04M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.57
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
1666.45%
Volume
Today's trading volume
449,223
Recent News
Biodesix, Inc. Q1 2026 Earnings Call Summary
Moby summary of Biodesix, Inc.'s Q1 2026 earnings call
Biodesix (BDSX) Q1 2026 Earnings Transcript
Scott Hutton: Thank you, Christopher F. Brinzey, and thank you all for joining today. Biodesix, Inc. delivered an exceptional start to 2026 with first quarter results that demonstrate continued momentum across our commercial, operational, and strategic priorities. Revenue growth accelerated, margins expanded, and we continued to demonstrate operating leverage as we progress towards profitability.
Biodesix Q1 Earnings Call Highlights
Biodesix (NASDAQ:BDSX) reported first-quarter 2026 results that company leadership said reflected accelerating revenue growth, expanding margins, and continued operating leverage as it works toward profitability. First-quarter results and updated outlook Chief Executive Officer Scott Hutton said Bi
Biodesix BDSX Q2 2025 Earnings Call Transcript
Scott Hutton: Thank you, Chris, and thank you all for joining us today. At Biodesix, our mission is to transform patient care and improve outcomes through personalized diagnostics that are timely, accessible and address immediate clinical needs.
Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates
Biodesix (BDSX) delivered earnings and revenue surprises of +35.71% and +12.33%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?